Amid a year of pandemic restrictions, India’s telemedicine startup Mfine has raised $16 million in its latest funding
round led by Singapore-based investor Heritas Capital and family office Y’S Investment.
Existing investors who also participated in the fundraising exercise include SBI Investment, SBI Ven Capital
BEENEXT, and Alteria Capital, the company said in a statement.
Founded in 2017, Mfine last raised $17.2 million in its Series B round in April 2019. The company says it will initiate
a Series C fundraising “in the coming months”.
The pandemic has driven the adoption of telemedicine across various markets. Investors have also piled into the
category with $4.3 billion in global VC funding in 2020, nearly 2.5 times higher than in the year before, according to
Mercom Capital.
Mfine is an artificial intelligence-enabled on-demand healthcare platform that provides users with virtual
consultations – it claims to be connected to over 4,000 doctors across 35 specialities. According to the company, since
COVID-19 hit, more than one million users have used its platform to consult with doctors remotely.
During 2020, it launched new services including AI-based self-assessment of various health conditions, and
expanded its coverage beyond key cities to more than 1,000 towns in India.
hile a part of the corpus will help Mfine develop its artificial intelligence, mobile engineering, and device
integration capabilities, the other part will be used to expand its hospital network across India, and ramp up its
recently-launched services in delivering medicines, preventive health screening, and diagnostic tests.
Mfine’s platform has the potential to grow beyond India, says SBI Investment’s chairman Yoshitaka Kitao in the
statement.
Mfine’s platform “will enable smart optimisation of limited healthcare resources,” Heritas CEO and executive
director Chik Wai Chiew added.
Heritas Capital is a private equity and venture capital firm that has also invested in Singapore-based biotech startup
Hummingbird Bioscience, and biopharmaceutical company Tessa Therapeutics.
South Africa Today
Read more at VolaNews
